+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
FEMALE
ID05076942

Phase II Study of Chemoradiation for Early Stage Vulvar Cancer with Sentinel Node Metastasis Larger Than 2mm

Led by University Medical Center Groningen · Updated on 2023-08-01

157

Participants Needed

27

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate a new treatment approach for early-stage vulvar cancer patients who have sentinel lymph node SN metastases larger than 2mm. Traditionally, these patients undergo an inguinofemoral lymphadenectomy IFL, a surgery linked to significant side effects like wound problems and leg swelling. Previous studies showed that radiotherapy alone was not enough for larger metastases, so this trial tests adding chemotherapy to improve treatment. Participants receive chemoradiation, which includes inguinofemoral radiotherapy totaling 56 Gy over 5 to 6 weeks, combined with weekly intravenous cisplatin chemotherapy. The radiotherapy is delivered in daily doses with a focused boost to affected lymph nodes. This study is a phase II trial designed to monitor safety and effectiveness, with rules to stop if groin recurrences become too frequent. During the study, participants will be closely monitored for groin recurrences within the first two years after treatment. Assessments include checking for treatment-related side effects, quality of life surveys specific to vulvar cancer, and regular follow-up visits. Researchers aim to gather detailed information about the safety of replacing surgery with chemoradiation and the impact on patients well-being over time.

CONDITIONS

Brief Title

Groningen International Study on Sentinel Nodes in Vulvar Cancer-III

Research Team

M

Maaike H Oonk, MD PhD

L

Liza Lahaye

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here